Recombinant Human Von Hippel Lindau His Protein

Von Hippel-Lindau disease(VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet(beta-domain) and a smaller alpha-helical domain(alpha-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF). VHL beta-domain(1-154aa) was overexpressed in E.coli and purified by using conventional chromatography techniques

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Showing Publication 1 - 1 of 1.

Publication using NBC1-18497	Applications	Species
Bashore FM, Foley CA, Ong HW et al. PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components ACS chemical biology 2023-03-17 [PMID: 36877831]

Array NBC1-18497

• Von Hippel Lindau Antibodies
• Von Hippel Lindau Lysate
• Von Hippel Lindau Protein